Watch our webinar with Nyrada, featuring CEO James Bonnar. A presentation followed by live Q&A with the audience.

Nyrada is a drug development company specialising in novel treatments for diseases where there is an unmet clinical need, or where current treatments are suboptimal. US incorporated, ASX listed, Australia headquartered, Nyrada is pioneering a family of small molecule drugs that target Transient Receptor Potential Cation (TRPC) channels. Its lead program is a first in class neuroprotection therapy for both traumatic brain injury (TBI) and stroke.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.